Status:
COMPLETED
Genetic Biomarker Discovery for Metastatic Prostate Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed r...
Eligibility Criteria
Inclusion
- Men age 18 years old and older.
- Histologically proven diagnosis of prostate cancer.
- Radiographic evidence of non-regional lymph node involvement, pelvic lymph node recurrence, and/or bone metastases.
- Requiring a clinically directed biopsy or resection of tumor at Mayo Clinic Rochester.
- Receiving local therapy for metastatic disease with radiation, ablative therapies, and/or surgery at Mayo Clinic Rochester.
- Willingness to provide blood sample prior to receipt of treatment, as well as after neoadjuvant androgen deprivation therapy and at 3 months and 6 months after radiation, ablation, or surgery.
- Absence of a second active malignancy.
- An understanding of the protocol and its requirements, risks, and discomforts.
- The ability and willingness to sign an informed consent.
Exclusion
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol.
- History of a serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).
Key Trial Info
Start Date :
May 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 9 2019
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03228810
Start Date
May 2 2017
End Date
April 9 2019
Last Update
May 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905